Welcome to the official LinkedIn page for the International Chronic Graft-versus-Host Disease Symposium!
Join us as we gather to explore the latest advancements in chronic graft-versus-host disease (cGvHD) research and treatment after allogeneic hematopoietic cell transplantation (alloHCT) and other cell therapies.
The 2026 Symposium is being organized by the Croatian Cooperative Group for Hematologic Diseases KroHem, with support from Cell Therapy Transplant Canada (CTTC). This symposium serves as a forum for interdisciplinary collaboration and international cooperation in the chronic GvHD field.
Stay tuned for updates and program highlights. We look forward to welcoming you to our next symposium!
Company Details
- Founded
- -
- Industry
- Hospitals And Health Care
- NAICS
-
Health Care and Social AssistanceSocial Assistance
- Website
- https://cgvhd-symposium.com/
- Keywords
- on this essential topic..
- Competitors
- University of Split School of Medicine, GvHD Hub, The Leukemia & Lymphoma Society of Canada, Rimac Energy, ICN-International Council of Nurses, CK-CARE, Christine Kühne - Center for Allergy Research and Education, ASTCT, Hematology/Oncology Pharmacy Association (HOPA), Science in Vancouver, KBC Split.
International Chronic Gvhd Symposium Questions
International Chronic Gvhd Symposium's website is https://cgvhd-symposium.com/
International Chronic Gvhd Symposium's LinkedIn profile is https://www.linkedin.com/company/cgvhd-symposium
International Chronic Gvhd Symposium's industry is
Hospitals and Health Care
International Chronic Gvhd Symposium's top competitors are
University Of Split School Of Medicine,
Gvhd Hub,
The Leukemia & Lymphoma Society Of Canada,
Rimac Energy,
Icn-International Council Of Nurses,
Ck-Care, Christine Kühne - Center For Allergy Research And Education,
Astct,
Hematology/oncology Pharmacy Association (Hopa),
Science In Vancouver,
Kbc Split.
International Chronic Gvhd Symposium's categories are Hospitals and Health Care
International Chronic Gvhd Symposium's founding year is 2013
